跳至主要内容
临床试验/NCT03123575
NCT03123575Unknown不适用

Polypharmacy and Clinically Significant Drug Interactions Among HIV-Infected Patients Receiving Antiretroviral Therapy in The Region Of Madrid: A Population-Based, Cross-Sectional Study

Hospital General Universitario Gregorio Marañon0 个研究点目标入组 1,000 人开始时间: 2017年6月最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
1,000
主要终点
the number of Co-meds in HIV-infected individuals on ART

研究概览

简要总结

This will be a cross-sectional population-based study carried out in the region of Madrid (6,468,322 inhabitants according to current census) to quantify the number of Co-meds in HIV-infected individuals on ART in the region of Madrid, categorized by age and gender, and to compare the number of Co-meds between the ART-treated population and HIV-uninfected population in the region of Madrid, categorized by age and gender.

详细描述

This will be a cross-sectional population-based study carried out in the region of Madrid (6,468,322 inhabitants according to current census) to quantify the number of Co-meds in HIV-infected individuals on ART in the region of Madrid, categorized by age and gender, and to compare the number of Co-meds between the ART-treated population and HIV-uninfected population in the region of Madrid, categorized by age and gender.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • patients who picked-up Co-meds in the study period

排除标准

  • 未提供

结局指标

主要结局

the number of Co-meds in HIV-infected individuals on ART

时间窗: 6 months

number of Co-meds in HIV-infected individuals on ART in the region of Madrid, categorized by age and gender.

number of Co-meds between the ART-treated population and HIV-uninfected

时间窗: 6 months

the number of Co-meds between the ART-treated population and HIV-uninfected population in the region of Madrid, categorized by age and gender.

prevalence of potential CSDIs between ARVs and Co-meds in ART-treated individuals

时间窗: 6 months

prevalence of potential CSDIs between ARVs and Co-meds in ART-treated individuals, with description of the types of harm expected from each different potential CSDIs identified

次要结局

未报告次要终点

研究者

发起方
Hospital General Universitario Gregorio Marañon
申办方类型
Other
责任方
Sponsor

相似试验

Polypharmacy and Clinically Significant Drug... | 临床试验